Page last updated: 2024-12-11
bms184476
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6918461 |
| CHEMBL ID | 4297267 |
| SCHEMBL ID | 12168429 |
| MeSH ID | M0387905 |
Synonyms (21)
| Synonym |
|---|
| bms-184476 |
| 7-methylthiomethylpaclitaxel |
| SCHEMBL12168429 |
| paclitaxel, 7-((methylthio)methyl)- |
| 7-((methylthio)methyl)paclitaxel |
| bms184476 |
| 3811w2nbz8 , |
| 7-o-((methylthio)methyl)paclitaxel |
| benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2ar,4s,4as,6r,9s,11s,12s,12ar,12bs)-6,12b-bis(acetyloxy)-12-(benzoyloxy)- 2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-4-((methylthio)methoxy)-5-oxo-7,11- |
| bms 184476 |
| 160237-25-2 |
| 7-methylthiomethyl-paclitaxel |
| unii-3811w2nbz8 |
| 7-methylthiomethylpaclitaxel [who-dd] |
| paclitaxel-7-methylthiomethyl ether |
| DB12633 |
| DTXSID30873340 |
| 7-[(methylthio)methyl]paclitaxel |
| [(1s,2s,3r,4s,7r,9s,10s,12r,15s)-4,12-diacetyloxy-15-[(2r,3s)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1-hydroxy-10,14,17,17-tetramethyl-9-(methylsulfanylmethoxy)-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate |
| Q27256717 |
| CHEMBL4297267 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Mean +/- SD values for clearance, volume of distribution at steady-state, and terminal half-life were 220 +/- 89 mL/min/m2, 402 +/- 231 L/m2, and 40." | ( Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. Aylesworth, C; Britten, CD; Felton, S; Ferrante, KJ; Gupta, E; Hammond, LA; Hidalgo, M; Molpus, K; Patnaik, A; Rowinsky, EK; Schwartz, G; Skillings, J; Smith, L; Sonnichsen, DS; Stephenson, J; Tortora, A; Weiss, G, 2001) | 0.31 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| "The aim of this study was to define the maximum tolerated dose (MTD) and the pharmacological profile of the paclitaxel analogue BMS-184476 given once every 3 weeks, or on days 1 and 8 every 3 weeks (d1&8), in combination with a fixed dose of 50 mg/m(2) of Doxorubicin (Doxo) administered on day 1 of a 21-day cycle." | ( Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin. Capri, G; Colombini, S; Gianni, L; Lladò, A; Locatelli, A; Marsoni, S; Minotti, G; Peccatori, F; Perotti, A; Salvatorelli, E; Sessa, C; Viganò, L; Voi, M, 2004) | 0.32 |
| "The aim of the study was to determine the maximum-tolerated dose and dose-limiting toxicities for BMS-184476, in combination with carboplatin, in patients with advanced solid tumours and to describe any preliminary antitumour activity associated with this regimen." | ( Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days. Bilenker, JH; Cohen, MB; Gallagher, ML; O'Dwyer, PJ; Stevenson, JP; Vaughn, D, 2004) | 0.32 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Neutropenia at the higher dose levels frequently prevented administration of the day 15 dose, and a modified schedule at MTD dosing on days 1 and 8 every 21 days was evaluated and found more feasible for Phase II studies." | ( Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies. Calvert, H; Calvert, P; Gallant, G; Ghielmini, M; Gupta, E; Plummer, R; Renard, J; Sessa, C; Voi, M, 2002) | 0.31 |
| " Dosing of BMS-184476 for 2 consecutive weeks allowed the administration of larger doses of the taxane with a promising antitumour activity in patients with untreated or minimally pretreated breast cancer." | ( Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin. Capri, G; Colombini, S; Gianni, L; Lladò, A; Locatelli, A; Marsoni, S; Minotti, G; Peccatori, F; Perotti, A; Salvatorelli, E; Sessa, C; Viganò, L; Voi, M, 2004) | 0.32 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.41
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.41) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (38.46%) | 5.53% |
| Reviews | 4 (30.77%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (30.77%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||